Breast Pathology

With the ever changing technologies and treatments available for patients diagnosed with breast cancer UniPath is proud to offer the latest testing available by anatomic pathology laboratories in addition to routine histopathologic interpretation.

UniPath offers a standard breast panel for invasive breast carcinoma: the panel consists of quantitative analysis of estrogen and progesterone receptors, Ki-67, and her2 gene amplification by FISH.

UniPath also offers an abbreviated panel for in situ breast carcinoma consisting of quantitation of estrogen and progesterone receptors.

UniPath provides reproducible quantification of Estrogen, Progesterone, Ki-67 (proliferative marker) and the Her2 protein scored by the FDA-approved ChromaVision. ChromaVision ACIS is a novel hardware and software imaging platform incorporating automated microscopy and advanced color recognition technology.

UniPath’s standard prognostic therapeutic panel includes Her2 gene quantification by FISH (fluorescence in situ hybridization) in place of or in addition to Her2 protein quantification by immunohistochemistry.

Other breast related markers offered by UniPath which may be of interest to you are:

  1. E-cadherin for characterization of ductal vs. lobular carcinoma.
  2. Myoepithelial markers (calponin, smooth muscle actin, CD10 and smooth muscle myosin heavy chain (SMMHC)) for detection of invasive carcinoma.
  3. Mammaglobin and BRST-2 (GCDFP) for detection of metastatic breast carcinoma.

All immunohistochemistry is performed and resulted daily. Her2FISH is performed on Monday and Wednesday with interpretation on Tuesday and Thursday. Results may be obtained through UniPath’s secured web reporting page. Speak with your UniPath representative for your log on and password so that you too may access your patient results.

Breast Pathology sample reports >>
 
  ^Back to Top^ All Content © 2006 UniPath, LLC